506 results on '"Jha, Manish K."'
Search Results
102. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial
103. sj-docx-1-jop-10.1177_0269881120985147 – Supplemental material for Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial
104. sj-docx-2-jop-10.1177_0269881120985147 – Supplemental material for Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial
105. Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study
106. Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence
107. Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life
108. Social construction of migrant identities: everyday life of Bangladeshi migrants in West Bengal
109. Risks and resilience: COVID-19 response and disaster management policies in India
110. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder
111. Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial
112. Social Policy and State–Community Relationships: Storm over Forest Rights in India
113. Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder
114. 'Stateless' Rohingyas: persecution, displacement and complex community development.
115. ‘Stateless’ Rohingyas: persecution, displacement and complex community development
116. What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI
117. Pharmacological Treatments for Patients with Treatment-Resistant Depression
118. Social Policy, COVID-19 and Impoverished Migrants: Challenges and Prospects in Locked Down India
119. Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study
120. Efficacy of Esketamine Augmentation in Major Depressive Disorder
121. Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis
122. Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder
123. 180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin
124. Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study
125. Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression
126. Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial
127. Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression—Advantage Ketamine?
128. Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial
129. Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study.
130. Connectivity seeded in the dorsolateral prefrontal and subcallosal cingulate cortices is associated with antidepressant response in Major Depressive Disorder
131. Elevated c-reactive protein is associated with worse acute-phase antidepressant response in women but not men: Findings from the EMBARC Study
132. Differential prediction of antidepressant treatment response via measurement of baseline adiponectin level: findings from the CO-MED randomized clinical trial
133. Psychopharmacology and Experimental Therapeutics for Bipolar Depression
134. Exploring the Association of Sex Differences and Exposure to Maternal Smoking With Low Fetal Growth
135. Expression of immune markers in post-mortem brain subjects of major depression and suicidality
136. MultiChannel Caucus based MAC (MC2-MAC) Protocol for LOS Communication in Smart Grids
137. When Discontinuing SSRI Antidepressants Is a Challenge: A Response to Letters to the Editor
138. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity
139. Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials
140. The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients
141. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
142. Mini Quality of Life Enjoyment and Satisfaction Questionnaire
143. When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips
144. Proteomics profiling of inflammation-related biomarkers in antidepressant treatment response: Findings from the CO-MED trial
145. An electroencephalographic signature predicts antidepressant response in major depression.
146. Brain regulation of emotional conflict predicts antidepressant treatment response for depression.
147. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
148. 5.68 Factors Related to Disorganized Attachment Style of Trauma-Affected Young Children in a Therapeutic Daycare Setting
149. Experimental Therapies for Treatment-Resistant Depression: Deciding When to Go to an Unproven or Experimental Therapy
150. Annihilation of Caste (The Annotated Critical Edition)1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.